<!DOCTYPE html>
<html >

<head>

  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>PhD thesis</title>
  <meta name="description" content="This is a PhD thesis written in real-time in Rstudio">
  <meta name="generator" content="bookdown 0.7 and GitBook 2.6.7">

  <meta property="og:title" content="PhD thesis" />
  <meta property="og:type" content="book" />
  
  
  <meta property="og:description" content="This is a PhD thesis written in real-time in Rstudio" />
  <meta name="github-repo" content="eliaseythorsson/phd_thesis" />

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="PhD thesis" />
  
  <meta name="twitter:description" content="This is a PhD thesis written in real-time in Rstudio" />
  

<meta name="author" content="Elías Sæbjörn Eyþórsson">


<meta name="date" content="2018-12-17">

  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black">
  
  
<link rel="prev" href="conclusions.html">

<script src="libs/jquery-2.2.3/jquery.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />










<link rel="stylesheet" href="style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./">PhD Thesis Under Construction</a></li>

<li class="divider"></li>
<li class="chapter" data-level="1" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i><b>1</b> Preamble</a></li>
<li class="chapter" data-level="2" data-path="intro.html"><a href="intro.html"><i class="fa fa-check"></i><b>2</b> Introduction</a><ul>
<li class="chapter" data-level="2.1" data-path="intro.html"><a href="intro.html#clinical-manifestations-of-streptococcus-pneumoniae"><i class="fa fa-check"></i><b>2.1</b> Clinical manifestations of <em>Streptococcus pneumoniae</em></a><ul>
<li class="chapter" data-level="2.1.1" data-path="intro.html"><a href="intro.html#acuteotitismediaintroduction"><i class="fa fa-check"></i><b>2.1.1</b> Acute otitis media</a></li>
<li class="chapter" data-level="2.1.2" data-path="intro.html"><a href="intro.html#pneumonia"><i class="fa fa-check"></i><b>2.1.2</b> Pneumonia</a></li>
<li class="chapter" data-level="2.1.3" data-path="intro.html"><a href="intro.html#invasive-pneumococcal-disease"><i class="fa fa-check"></i><b>2.1.3</b> Invasive pneumococcal disease</a></li>
</ul></li>
<li class="chapter" data-level="2.2" data-path="intro.html"><a href="intro.html#pneumococcal-vaccines"><i class="fa fa-check"></i><b>2.2</b> Pneumococcal vaccines</a><ul>
<li class="chapter" data-level="2.2.1" data-path="intro.html"><a href="intro.html#a-brief-history-of-pneumococcal-vaccination"><i class="fa fa-check"></i><b>2.2.1</b> A brief history of pneumococcal vaccination</a></li>
<li class="chapter" data-level="2.2.2" data-path="intro.html"><a href="intro.html#key-concepts-in-pneumococcal-vaccine-epidemiology"><i class="fa fa-check"></i><b>2.2.2</b> Key concepts in pneumococcal vaccine epidemiology</a></li>
<li class="chapter" data-level="2.2.3" data-path="intro.html"><a href="intro.html#the-impact-of-pneumococcal-conjugate-vaccines-on-otitis-media"><i class="fa fa-check"></i><b>2.2.3</b> The impact of pneumococcal conjugate vaccines on otitis media</a></li>
<li class="chapter" data-level="2.2.4" data-path="intro.html"><a href="intro.html#the-impact-of-pneumococcal-conjugate-vaccines-on-pneumonia"><i class="fa fa-check"></i><b>2.2.4</b> The impact of pneumococcal conjugate vaccines on pneumonia</a></li>
<li class="chapter" data-level="2.2.5" data-path="intro.html"><a href="intro.html#the-impact-of-pneumococcal-conjugate-vaccines-on-invasive-pneumococcal-disease"><i class="fa fa-check"></i><b>2.2.5</b> The impact of pneumococcal conjugate vaccines on Invasive pneumococcal disease</a></li>
</ul></li>
<li class="chapter" data-level="2.3" data-path="intro.html"><a href="intro.html#cea-introduction"><i class="fa fa-check"></i><b>2.3</b> Cost-effectiveness in the context of pneumococcal conjugate vaccination</a><ul>
<li class="chapter" data-level="2.3.1" data-path="intro.html"><a href="intro.html#vaccine-efficacy-assumptions-in-economic-analyses-of-pneumococcal-conjugate-vaccines"><i class="fa fa-check"></i><b>2.3.1</b> Vaccine efficacy assumptions in economic analyses of pneumococcal conjugate vaccines</a></li>
<li class="chapter" data-level="2.3.2" data-path="intro.html"><a href="intro.html#assumptions-regarding-costs-and-utilities-in-economic-analyses-of-pneumococcal-vaccines"><i class="fa fa-check"></i><b>2.3.2</b> Assumptions regarding costs and utilities in economic analyses of pneumococcal vaccines</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="3" data-path="aims.html"><a href="aims.html"><i class="fa fa-check"></i><b>3</b> Aims</a></li>
<li class="chapter" data-level="4" data-path="methods.html"><a href="methods.html"><i class="fa fa-check"></i><b>4</b> Materials and methods</a><ul>
<li class="chapter" data-level="4.1" data-path="methods.html"><a href="methods.html#datasources"><i class="fa fa-check"></i><b>4.1</b> Data collection and sources</a><ul>
<li class="chapter" data-level="4.1.1" data-path="methods.html"><a href="methods.html#statisticsiceland"><i class="fa fa-check"></i><b>4.1.1</b> Statistics Iceland</a></li>
<li class="chapter" data-level="4.1.2" data-path="methods.html"><a href="methods.html#patientregistry"><i class="fa fa-check"></i><b>4.1.2</b> Landspitali University Hospital patient registry</a></li>
<li class="chapter" data-level="4.1.3" data-path="methods.html"><a href="methods.html#primarycareregistry"><i class="fa fa-check"></i><b>4.1.3</b> The Primary Care Registry</a></li>
<li class="chapter" data-level="4.1.4" data-path="methods.html"><a href="methods.html#vaccineregistry"><i class="fa fa-check"></i><b>4.1.4</b> The National Vaccine Registry</a></li>
<li class="chapter" data-level="4.1.5" data-path="methods.html"><a href="methods.html#prescriptionregistry"><i class="fa fa-check"></i><b>4.1.5</b> The National Drug Prescription Registry</a></li>
<li class="chapter" data-level="4.1.6" data-path="methods.html"><a href="methods.html#reimbursementdatabase"><i class="fa fa-check"></i><b>4.1.6</b> Reimbursement database of Icelandic Health Insurance</a></li>
</ul></li>
<li class="chapter" data-level="4.2" data-path="methods.html"><a href="methods.html#paper1"><i class="fa fa-check"></i><b>4.2</b> Impact on otitis media with treatment failure (Paper I)</a></li>
<li class="chapter" data-level="4.3" data-path="methods.html"><a href="methods.html#paper2"><i class="fa fa-check"></i><b>4.3</b> Impact on primary care visits for otitis media (Paper II)</a></li>
<li class="chapter" data-level="4.4" data-path="methods.html"><a href="methods.html#paper3"><i class="fa fa-check"></i><b>4.4</b> Impact on outpatient antimicrobial prescriptions (Paper III)</a></li>
<li class="chapter" data-level="4.5" data-path="methods.html"><a href="methods.html#paper4"><i class="fa fa-check"></i><b>4.5</b> Impact on tympanostomy tube procedures (Paper IV)</a></li>
<li class="chapter" data-level="4.6" data-path="methods.html"><a href="methods.html#paper5"><i class="fa fa-check"></i><b>4.6</b> Impact on respiratory associated hospitalizations (Paper V)</a></li>
<li class="chapter" data-level="4.7" data-path="methods.html"><a href="methods.html#paper6"><i class="fa fa-check"></i><b>4.7</b> Impact and cost-effectiveness analysis (Paper VI)</a><ul>
<li class="chapter" data-level="4.7.1" data-path="methods.html"><a href="methods.html#data-sources"><i class="fa fa-check"></i><b>4.7.1</b> Data sources</a></li>
<li class="chapter" data-level="4.7.2" data-path="methods.html"><a href="methods.html#statistical-analysis"><i class="fa fa-check"></i><b>4.7.2</b> Statistical analysis</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="5" data-path="results.html"><a href="results.html"><i class="fa fa-check"></i><b>5</b> Results</a><ul>
<li class="chapter" data-level="5.1" data-path="results.html"><a href="results.html#datasourcesresults"><i class="fa fa-check"></i><b>5.1</b> Data collection and sources</a><ul>
<li class="chapter" data-level="5.1.1" data-path="results.html"><a href="results.html#statistics-iceland"><i class="fa fa-check"></i><b>5.1.1</b> Statistics Iceland</a></li>
<li class="chapter" data-level="5.1.2" data-path="results.html"><a href="results.html#landspitali-university-hospital-patient-registry"><i class="fa fa-check"></i><b>5.1.2</b> Landspitali University Hospital patient registry</a></li>
<li class="chapter" data-level="5.1.3" data-path="results.html"><a href="results.html#the-primary-care-registry"><i class="fa fa-check"></i><b>5.1.3</b> The Primary Care Registry</a></li>
<li class="chapter" data-level="5.1.4" data-path="results.html"><a href="results.html#the-national-vaccine-registry"><i class="fa fa-check"></i><b>5.1.4</b> The National Vaccine Registry</a></li>
<li class="chapter" data-level="5.1.5" data-path="results.html"><a href="results.html#the-national-drug-prescription-registry"><i class="fa fa-check"></i><b>5.1.5</b> The National Drug Prescription Registry</a></li>
<li class="chapter" data-level="5.1.6" data-path="results.html"><a href="results.html#reimbursement-database-of-icelandic-health-insurance"><i class="fa fa-check"></i><b>5.1.6</b> Reimbursement database of Icelandic Health Insurance</a></li>
</ul></li>
<li class="chapter" data-level="5.2" data-path="results.html"><a href="results.html#paper1results"><i class="fa fa-check"></i><b>5.2</b> Impact on otitis media with treatment failure (Paper I)</a></li>
<li class="chapter" data-level="5.3" data-path="results.html"><a href="results.html#paper2results"><i class="fa fa-check"></i><b>5.3</b> Impact on primary care visits for otitis media (Paper II)</a></li>
<li class="chapter" data-level="5.4" data-path="results.html"><a href="results.html#paper3results"><i class="fa fa-check"></i><b>5.4</b> Impact on outpatient antimicrobial prescriptions (Paper III)</a></li>
<li class="chapter" data-level="5.5" data-path="results.html"><a href="results.html#paper4results"><i class="fa fa-check"></i><b>5.5</b> Impact on tympanostomy tube procedures (Paper IV)</a></li>
<li class="chapter" data-level="5.6" data-path="results.html"><a href="results.html#paper5results"><i class="fa fa-check"></i><b>5.6</b> Impact on respiratory associated hospitalizations (Paper V)</a></li>
</ul></li>
<li class="chapter" data-level="6" data-path="discussion.html"><a href="discussion.html"><i class="fa fa-check"></i><b>6</b> Discussion</a><ul>
<li class="chapter" data-level="6.1" data-path="discussion.html"><a href="discussion.html#main-findings"><i class="fa fa-check"></i><b>6.1</b> Main findings</a></li>
<li class="chapter" data-level="6.2" data-path="discussion.html"><a href="discussion.html#datasourcesdiscussion"><i class="fa fa-check"></i><b>6.2</b> Data collection and sources</a></li>
<li class="chapter" data-level="6.3" data-path="discussion.html"><a href="discussion.html#epidemiology-and-impact-of-phid-cv10-on-otitis-media-in-iceland-papers-i-ii-iii-v-and-vi"><i class="fa fa-check"></i><b>6.3</b> Epidemiology and impact of PHiD-CV10 on otitis media in Iceland (Papers I, II, III, V and VI)</a><ul>
<li class="chapter" data-level="6.3.1" data-path="discussion.html"><a href="discussion.html#epidemiology-of-acute-otitis-media-in-iceland-papers-ii-and-v"><i class="fa fa-check"></i><b>6.3.1</b> Epidemiology of acute otitis media in Iceland (Papers II and V)</a></li>
<li class="chapter" data-level="6.3.2" data-path="discussion.html"><a href="discussion.html#impact-on-primary-care-visits-for-otitis-media-papers-ii-and-vi"><i class="fa fa-check"></i><b>6.3.2</b> Impact on primary care visits for otitis media (Papers II and VI)</a></li>
<li class="chapter" data-level="6.3.3" data-path="discussion.html"><a href="discussion.html#impact-on-pediatric-emergency-department-visits-for-acute-otitis-media-paper-i"><i class="fa fa-check"></i><b>6.3.3</b> Impact on pediatric emergency department visits for acute otitis media (Paper I)</a></li>
<li class="chapter" data-level="6.3.4" data-path="discussion.html"><a href="discussion.html#impact-on-outpatient-antimicrobial-prescriptions-for-otitis-media-paper-iii"><i class="fa fa-check"></i><b>6.3.4</b> Impact on outpatient antimicrobial prescriptions for otitis media (Paper III)</a></li>
<li class="chapter" data-level="6.3.5" data-path="discussion.html"><a href="discussion.html#impact-on-acute-otitis-media-with-treatment-failure-paper-i"><i class="fa fa-check"></i><b>6.3.5</b> Impact on acute otitis media with treatment failure (Paper I)</a></li>
<li class="chapter" data-level="6.3.6" data-path="discussion.html"><a href="discussion.html#impact-on-hospital-admissions-for-otitis-media-paper-v"><i class="fa fa-check"></i><b>6.3.6</b> Impact on hospital admissions for otitis media (Paper V)</a></li>
<li class="chapter" data-level="6.3.7" data-path="discussion.html"><a href="discussion.html#evidence-of-herd-effect-of-phid-cv10-on-the-incidence-of-otitis-media-in-the-unvaccinated-population-papers-ii-and-vi"><i class="fa fa-check"></i><b>6.3.7</b> Evidence of herd-effect of PHiD-CV10 on the incidence of otitis media in the unvaccinated population (Papers II and VI)</a></li>
</ul></li>
<li class="chapter" data-level="6.4" data-path="discussion.html"><a href="discussion.html#impact-of-phid-cv10-on-tympanostomy-tube-placements-paper-iv"><i class="fa fa-check"></i><b>6.4</b> Impact of PHiD-CV10 on tympanostomy tube placements (Paper IV)</a></li>
<li class="chapter" data-level="6.5" data-path="discussion.html"><a href="discussion.html#impact-of-phid-cv10-on-pneumonia-in-iceland-papers-v-and-vi"><i class="fa fa-check"></i><b>6.5</b> Impact of PHiD-CV10 on pneumonia in Iceland (Papers V and VI)</a><ul>
<li class="chapter" data-level="6.5.1" data-path="discussion.html"><a href="discussion.html#impact-on-pneumonia-hospitalizations-papers-v-and-vi"><i class="fa fa-check"></i><b>6.5.1</b> Impact on pneumonia hospitalizations (Papers V and VI)</a></li>
<li class="chapter" data-level="6.5.2" data-path="discussion.html"><a href="discussion.html#evidence-of-herd-effect-of-phid-cv10-on-the-incidence-of-pneumonia-hospitalization-in-the-unvaccinated-population-papers-v-and-vi"><i class="fa fa-check"></i><b>6.5.2</b> Evidence of herd-effect of PHiD-CV10 on the incidence of pneumonia hospitalization in the unvaccinated population (Papers V and VI)</a></li>
</ul></li>
<li class="chapter" data-level="6.6" data-path="discussion.html"><a href="discussion.html#impact-of-phid-cv10-on-invasive-pneumococcal-disease-papers-v-and-vi"><i class="fa fa-check"></i><b>6.6</b> Impact of PHiD-CV10 on invasive pneumococcal disease (Papers V and VI)</a></li>
<li class="chapter" data-level="6.7" data-path="discussion.html"><a href="discussion.html#cost-effectiveness-of-introduction-of-phid-cv10-into-the-icelandic-pediatric-vaccination-program-paper-vi"><i class="fa fa-check"></i><b>6.7</b> Cost-effectiveness of introduction of PHiD-CV10 into the Icelandic pediatric vaccination program (Paper VI)</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="conclusions.html"><a href="conclusions.html"><i class="fa fa-check"></i><b>7</b> Conclusions</a></li>
<li class="chapter" data-level="" data-path="references.html"><a href="references.html"><i class="fa fa-check"></i>References</a></li>
<li class="divider"></li>
<li><a href="https://github.com/rstudio/bookdown" target="blank">Published with bookdown</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">PhD thesis</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="references" class="section level1 unnumbered">
<h1>References</h1>

<div id="refs" class="references">
<div>
<p>Andersen, P. K., and R. D. Gill. 1982. “Cox’s Regression Model for Counting Processes: A Large Sample Study.” <em>The Annals of Statistics</em> 10 (4): 1100–1120. doi:<a href="https://doi.org/10.1214/aos/1176345976">10.1214/aos/1176345976</a>.</p>
</div>
<div>
<p>Andrade, Luiz Flavio, Grèce Saba, Jean-Damien Ricard, Jonathan Messika, Jacques Gaillat, Pierre Bonnin, Christian Chidiac, et al. 2018. “Health related quality of life in patients with community-acquired pneumococcal pneumonia in France.” <em>Health and Quality of Life Outcomes</em> 16 (1). Health; Quality of Life Outcomes: 28. doi:<a href="https://doi.org/10.1186/s12955-018-0854-6">10.1186/s12955-018-0854-6</a>.</p>
</div>
<div>
<p>Arason, Vilhjalmur A, Johann A Sigurdsson, Karl G Kristinsson, and Sigurdur Gudmundsson. 2002. “Tympanostomy tube placements, sociodemographic factors and parental expectations for management of acute otitis media in Iceland.” <em>The Pediatric Infectious Disease Journal</em> 21 (12): 1110–5. doi:<a href="https://doi.org/10.1097/01.inf.0000040702.00373.95">10.1097/01.inf.0000040702.00373.95</a>.</p>
</div>
<div>
<p>Arason, Vilhjalmur A., Johann A. Sigurdsson, Karl G. Kristinsson, Linn Getz, and Sigurdur Gudmundsson. 2005. “Otitis media, tympanostomy tube placement, and use of antibiotics.” <em>Scandinavian Journal of Primary Health Care</em> 23 (3). Taylor &amp; Francis: 184–91. doi:<a href="https://doi.org/10.1080/02813430510031298">10.1080/02813430510031298</a>.</p>
</div>
<div>
<p>Austrian, R, R M Douglas, G Schiffman, A M Coetzee, H J Koornhof, S Hayden-Smith, and R D Reid. 1976. “Prevention of pneumococcal pneumonia by vaccination.” <em>Transactions of the Association of American Physicians</em> 89: 184–94. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14433" class="uri">http://www.ncbi.nlm.nih.gov/pubmed/14433</a>.</p>
</div>
<div>
<p>Austrian, Robert. 1981. “Pneumococcus: the first one hundred years.” <em>Reviews of Infectious Diseases</em> 3 (2): 183–9. doi:<a href="https://doi.org/10.1093/clinids/3.2.183">10.1093/clinids/3.2.183</a>.</p>
</div>
<div>
<p>———. 1999. “A brief history of pneumococcal vaccines.” <em>Drugs &amp; Aging</em> 15 Suppl 1: 1–10. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10690790" class="uri">http://www.ncbi.nlm.nih.gov/pubmed/10690790</a>.</p>
</div>
<div>
<p>Austrian, Robert, and J Gold. 1964. “Pneumococcal Bacteremia with Especial Reference to Bacteremic Pneumococcal Pneumonia.” <em>Annals of Internal Medicine</em> 60: 759–76. doi:<a href="https://doi.org/10.7326/0003-4819-60-5-759">10.7326/0003-4819-60-5-759</a>.</p>
</div>
<div>
<p>Ben-Shimol, Shalom, Noga Givon-Lavi, Eugene Leibovitz, Simon Raiz, David Greenberg, and Ron Dagan. 2016. “Impact of Widespread Introduction of Pneumococcal Conjugate Vaccines on Pneumococcal and Nonpneumococcal Otitis Media.” <em>Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America</em> 63 (5): 611–8. doi:<a href="https://doi.org/10.1093/cid/ciw347">10.1093/cid/ciw347</a>.</p>
</div>
<div>
<p>Bennett, Jonathan E., Walton Sumner, Stephen M. Downs, and David M. Jaffe. 2000. “Parents’ Utilities for Outcomes of Occult Bacteremia.” <em>Archives of Pediatrics &amp; Adolescent Medicine</em> 154 (1). American Medical Association: 43–48. doi:<a href="https://doi.org/10-1001/pubs.Pediatr Adolesc Med.-ISSN-1072-4710-154-1-poa9043">10-1001/pubs.Pediatr Adolesc Med.-ISSN-1072-4710-154-1-poa9043</a>.</p>
</div>
<div>
<p>Beutels, Philippe, Nancy Thiry, and Pierre Van Damme. 2007. “Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination–a review (2002-2006).” <em>Vaccine</em> 25 (8): 1355–67. doi:<a href="https://doi.org/10.1016/j.vaccine.2006.10.034">10.1016/j.vaccine.2006.10.034</a>.</p>
</div>
<div>
<p>Bjarnason, Skúli, Ingþór Friðriksson, and Jón Benediktsson. 1991. “Tíðni bráðrar miðeyrabólgu hjá börnum á svæði heilsugæslustöðvarinnar Borgarnesi.” <em>Læknablaðið</em> 77 (4): 137–40. <a href="http://www.hirsla.lsh.is/lsh/bitstream/2336/90415/1/L1991-04-77-F3.pdf" class="uri">http://www.hirsla.lsh.is/lsh/bitstream/2336/90415/1/L1991-04-77-F3.pdf</a>.</p>
</div>
<div>
<p>Black, Nick. 1984. “SURGERY FOR GLUE EAR —A MODERN EPIDEMIC.” <em>The Lancet</em> 323 (8381): 835–37. doi:<a href="https://doi.org/10.1016/S0140-6736(84)92280-3">10.1016/S0140-6736(84)92280-3</a>.</p>
</div>
<div>
<p>Black, S, H Shinefield, Bruce Fireman, E Lewis, P Ray, J R Hansen, L Elvin, et al. 2000. “Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.” <em>The Pediatric Infectious Disease Journal</em> 19 (3): 187–95. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10749457" class="uri">http://www.ncbi.nlm.nih.gov/pubmed/10749457</a>.</p>
</div>
<div>
<p>Black, Steven B, and H Shinefield. 2002. “Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California.” <em>Eur J Pediatr</em> 161 Suppl: S127–31. doi:<a href="https://doi.org/10.1007/s00431-002-1064-z">10.1007/s00431-002-1064-z</a>.</p>
</div>
<div>
<p>Black, Steven B, H R Shinefield, S Ling, J Hansen, Bruce Fireman, D Spring, J Noyes, et al. 2002. “Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia.” <em>Pediatr Infect Dis J</em> 21 (9): 810–15. doi:<a href="https://doi.org/10.1097/01.inf.0000027926.99356.4c">10.1097/01.inf.0000027926.99356.4c</a>.</p>
</div>
<div>
<p>Blank, Patricia R., and Thomas D. Szucs. 2012. “Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland.” <em>Vaccine</em> 30 (28): 4267–75. doi:<a href="https://doi.org/10.1016/j.vaccine.2012.04.028">10.1016/j.vaccine.2012.04.028</a>.</p>
</div>
<div>
<p>Block, Stan L., James Hedrick, Christopher J. Harrison, Ron Tyler, Alan Smith, Rebecca Findlay, and Eileen Keegan. 2004. “Community-Wide Vaccination with the Heptavalent Pneumococcal Conjugate Significantly Alters the Microbiology of Acute Otitis Media.” <em>The Pediatric Infectious Disease Journal</em> 23 (9): 829–33. doi:<a href="https://doi.org/10.1097/01.inf.0000136868.91756.80">10.1097/01.inf.0000136868.91756.80</a>.</p>
</div>
<div>
<p>Bluestone, C D, J S Stephenson, and L M Martin. 1992. “Ten-year review of otitis media pathogens.” <em>The Pediatric Infectious Disease Journal</em> 11 (8 Suppl): S7–11. doi:<a href="https://doi.org/10.1097/00006454-199208001-00002">10.1097/00006454-199208001-00002</a>.</p>
</div>
<div>
<p>Bright, R A, R M Moore, L L Jeng, C M Sharkness, S E Hamburger, and P M Hamilton. 1993. “The prevalence of tympanostomy tubes in children in the United States, 1988.” <em>American Journal of Public Health</em> 83 (7): 1026–8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8328599 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC1694786" class="uri">http://www.ncbi.nlm.nih.gov/pubmed/8328599 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC1694786</a>.</p>
</div>
<div>
<p>Browning, George G, Maroeska M Rovers, Ian Williamson, Jørgen Lous, and Martin J Burton. 2010. “Grommets (ventilation tubes) for hearing loss associated with otitis media with effusion in children.” <em>Cochrane Database of Systematic Reviews</em>, no. 10 (October). doi:<a href="https://doi.org/10.1002/14651858.CD001801.pub3">10.1002/14651858.CD001801.pub3</a>.</p>
</div>
<div>
<p>Bruhn, Christian A W, Stephen Hetterich, Cynthia Schuck-Paim, Esra Kürüm, Robert J Taylor, Roger Lustig, Eugene D Shapiro, Joshua L Warren, Lone Simonsen, and Daniel M Weinberger. 2017. “Estimating the population-level impact of vaccines using synthetic controls.” <em>Proceedings of the National Academy of Sciences</em> 114 (7): 1524–9. doi:<a href="https://doi.org/10.1073/pnas.1612833114">10.1073/pnas.1612833114</a>.</p>
</div>
<div>
<p>By, Åsa, Patrik Sobocki, Arne Forsgren, and Sven-Arne Silfverdal. 2012. “Comparing Health Outcomes and Costs of General Vaccination with Pneumococcal Conjugate Vaccines in Sweden: A Markov Model.” <em>Clinical Therapeutics</em> 34 (1): 177–89. doi:<a href="https://doi.org/10.1016/j.clinthera.2011.12.007">10.1016/j.clinthera.2011.12.007</a>.</p>
</div>
<div>
<p>Byford, S, and J Raftery. 1998. “Economics notes: Perspectives in economic evaluation.” <em>BMJ</em> 316 (7143): 1529–30. doi:<a href="https://doi.org/10.1136/bmj.316.7143.1529">10.1136/bmj.316.7143.1529</a>.</p>
</div>
<div>
<p>Casey, Janet R, Diana G Adlowitz, and Michael E Pichichero. 2009. “New Patterns in the Otopathogens Causing Acute Otitis Media Six to Eight Years After Introduction of Pneumococcal Conjugate Vaccine.” <em>The Pediatric Infectious Disease Journal</em> 29 (November): 1. doi:<a href="https://doi.org/10.1097/INF.0b013e3181c1bc48">10.1097/INF.0b013e3181c1bc48</a>.</p>
</div>
<div>
<p>Casey, Janet R., and Michael E. Pichichero. 2004. “Changes in frequency and pathogens causing acute otitis media in 1995-2003.” <em>The Pediatric Infectious Disease Journal</em> 23 (9): 824–8. doi:<a href="https://doi.org/10.1097/01.inf.0000136871.51792.19">10.1097/01.inf.0000136871.51792.19</a>.</p>
</div>
<div>
<p>Castiglia, Paolo, Lorenzo Pradelli, Stefano Castagna, Veronica Freguglia, Giorgio Palù, and Susanna Esposito. 2017. “Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.” <em>Human Vaccines &amp; Immunotherapeutics</em> 13 (10). Taylor &amp; Francis: 2307–15. doi:<a href="https://doi.org/10.1080/21645515.2017.1343773">10.1080/21645515.2017.1343773</a>.</p>
</div>
<div>
<p>Cecil, R. L. 1918. “RESULTS OF PROPHYLACTIC INOCULATION AGAINST PNEUMOCOCCUS IN 12,519 MEN.” <em>Journal of Experimental Medicine</em> 28 (1): 19–41. doi:<a href="https://doi.org/10.1084/jem.28.1.19">10.1084/jem.28.1.19</a>.</p>
</div>
<div>
<p>Chen, Yi-Jen, Yu-Chia Hsieh, Yhu-Chering Huang, and Cheng-Hsun Chiu. 2013. “Clinical manifestations and microbiology of acute otitis media with spontaneous otorrhea in children.” <em>Journal of Microbiology, Immunology and Infection</em> 46 (5). Elsevier Taiwan LLC: 382–88. doi:<a href="https://doi.org/10.1016/j.jmii.2013.04.001">10.1016/j.jmii.2013.04.001</a>.</p>
</div>
<div>
<p>Chuck, Anderson W., Philip Jacobs, Gregory Tyrell, and James D. Kellner. 2010. “Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines.” <em>Vaccine</em> 28: 5485–90. doi:<a href="https://doi.org/10.1016/j.vaccine.2010.05.058">10.1016/j.vaccine.2010.05.058</a>.</p>
</div>
<div>
<p>Cilloniz, Catia, Ignacio Martin-Loeches, Carolina Garcia-Vidal, Alicia San Jose, and Antoni Torres. 2016. “Microbial etiology of pneumonia: Epidemiology, diagnosis and resistance patterns.” <em>International Journal of Molecular Sciences</em> 17 (12). doi:<a href="https://doi.org/10.3390/ijms17122120">10.3390/ijms17122120</a>.</p>
</div>
<div>
<p>CLAESSON, BO A., BIRGER TROLLFORS, INGER BROLIN, MARTA GRANSTRÖM, JØRGEN HENRICHSEN, ULF JODAL, PER JUTO, et al. 1989. “Etiology of community-acquired pneumonia in children based on antibody responses to bacterial and viral antigens.” <em>The Pediatric Infectious Disease Journal</em> 8 (12): 856–61. doi:<a href="https://doi.org/10.1097/00006454-198912000-00006">10.1097/00006454-198912000-00006</a>.</p>
</div>
<div>
<p>Claxton, Karl, Mike Paulden, Hugh Gravelle, Werner Brouwer, and Anthony J. Culyer. 2011. “Discounting and decision making in the economic evaluation of health-care technologies.” <em>Health Economics</em> 20 (1): 2–15. doi:<a href="https://doi.org/10.1002/hec.1612">10.1002/hec.1612</a>.</p>
</div>
<div>
<p>co-operation, Organisation for economic, and development. 2013. “PF3 . 2 : Enrolment in childcare and pre-schools.” <em>Social Policies and Data, OECD Family Database</em>, 3–8. <a href="http://www.oecd.org/social/soc/oecdfamilydatabase.htm" class="uri">http://www.oecd.org/social/soc/oecdfamilydatabase.htm</a>.</p>
</div>
<div>
<p>Cook, Richard J. (Richard John), and Jerald F. Lawless. 2007a. <em>The Statistical Analysis of Recurrent Events</em>. Edited by M Gail, K Krickeberg, J Sarmet, A Tsiatis, and W Wong. New York: Springer Science + Business Media.</p>
</div>
<div>
<p>———. 2007b. <em>The statistical analysis of recurrent events</em>. Springer.</p>
</div>
<div>
<p>Cullen, Karen A, Margaret J Hall, and Aleksandr Golosinskiy. 2009. “Ambulatory surgery in the United States, 2006.” <em>National Health Statistics Reports</em>, no. 11 (January): 1–25. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19294964" class="uri">http://www.ncbi.nlm.nih.gov/pubmed/19294964</a>.</p>
</div>
<div>
<p>Dagan, Ron, M Sikuler-Cohen, O Zamir, J Janco, Noga Givon-Lavi, and D Fraser. 2001. “Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees.” <em>Pediatr Infect Dis J</em> 20 (10): 951–58. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11642629" class="uri">http://www.ncbi.nlm.nih.gov/pubmed/11642629</a>.</p>
</div>
<div>
<p>Davies, John A. V. 1937. “The Response of Infants to Inoculation with Type I Pneumococcus Carbohydrate.” <em>The Journal of Immunology</em>.</p>
</div>
<div>
<p>Deibel, RH, and HW Seeley. 1974. “Family II: Streptococcuceae.” In <em>Bergey’s Manual of Determinative Bacteriology</em>, edited by R. E. Buchanan and N. E. Gibbons, 8th ed., 490–517. Baltimore: The William; Wilkins Co.</p>
</div>
<div>
<p>Delgleize, Emmanuelle, Oscar Leeuwenkamp, Eleni Theodorou, and Nicolas Van de Velde. 2016. “Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.” <em>BMJ Open</em> 6 (11): e010776. doi:<a href="https://doi.org/10.1136/bmjopen-2015-010776">10.1136/bmjopen-2015-010776</a>.</p>
</div>
<div>
<p>Díez-Domingo, Javier, Manuel Ridao-López, M Victoria Gutiérrez-Gimeno, Joan Puig-Barberá, Jose a Lluch-Rodrigo, and Eliseo Pastor-Villalba. 2011. “Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).” <em>Vaccine</em> 29 (52). Elsevier Ltd: 9640–8. doi:<a href="https://doi.org/10.1016/j.vaccine.2011.10.038">10.1016/j.vaccine.2011.10.038</a>.</p>
</div>
<div>
<p>Dochez, A Lz, and O T Avery. 1917. “The elaboration of specific soluble substance by pneumococcus during growth.” <em>The Journal of Experimental Medicine</em>. doi:<a href="https://doi.org/10.1084/jem.26.4.477">10.1084/jem.26.4.477</a>.</p>
</div>
<div>
<p>Dowling, John N, Paul R Sheehe, and Harry A Feldman. 1971. “Pharyngeal pneumococcal acquisitions in ‘normal’ families: a longitudinal study.” <em>The Journal of Infectious Diseases</em> 124 (1): 9–17. <a href="http://www.ncbi.nlm.nih.gov/pubmed/4401272" class="uri">http://www.ncbi.nlm.nih.gov/pubmed/4401272</a>.</p>
</div>
<div>
<p>Dvorzak, Michaela, and Helga Wagner. 2016. <em>Pogit: Bayesian Variable Selection for a Poisson-Logistic Model</em>. <a href="https://CRAN.R-project.org/package=pogit" class="uri">https://CRAN.R-project.org/package=pogit</a>.</p>
</div>
<div>
<p>Earnshaw, Stephanie R, Cheryl L McDade, Giovanni Zanotti, Raymond A Farkouh, and David Strutton. 2012. “Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.” <em>BMC Infectious Diseases</em> 12 (1): 101. doi:<a href="https://doi.org/10.1186/1471-2334-12-101">10.1186/1471-2334-12-101</a>.</p>
</div>
<div>
<p>Ekwurzel, G M, J S Simmons, L I Dublin, and L D Felton. 1938. “Studies on immunizing substances in pneumococci. VIII. Report on field tests to determine the prophylactic value of a pneumococcus antigen.” <em>Public Health Rep</em> 53 (42): 1877–93.</p>
</div>
<div>
<p>Elemraid, Mohamed A., Andrew D. Sails, Gary J.A. Eltringham, John D. Perry, Stephen P. Rushton, David A. Spencer, Matthew F. Thomas, et al. 2013. “Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine.” <em>European Respiratory Journal</em> 42 (6): 1595–1603. doi:<a href="https://doi.org/10.1183/09031936.00199112">10.1183/09031936.00199112</a>.</p>
</div>
<div>
<p>Eskola, J, T. Kilpi, A. Palmu, J. Jokinen, J. Haapakoski, E. Herva, A. Takala, et al. 2001. “Efficacy of a pneumococcal conjugate vaccine against acute otitis media.” <em>N Engl J Med</em> 344 (6): 403–9. doi:<a href="https://doi.org/10.1056/nejm200102083440602">10.1056/nejm200102083440602</a>.</p>
</div>
<div>
<p>Eurostat. 2018. “Employment statistics.” <a href="https://ec.europa.eu/eurostat/statistics-explained/index.php/Employment{\_}statistics" class="uri">https://ec.europa.eu/eurostat/statistics-explained/index.php/Employment{\_}statistics</a>.</p>
</div>
<div>
<p>Feikin, Daniel R., Laura L. Hammitt, David R. Murdoch, Katherine L. O’Brien, and J. Anthony G. Scott. 2017. “The Enduring Challenge of Determining Pneumonia Etiology in Children: Considerations for Future Research Priorities.” <em>Clinical Infectious Diseases</em> 64 (suppl_3): S188–S196. doi:<a href="https://doi.org/10.1093/cid/cix143">10.1093/cid/cix143</a>.</p>
</div>
<div>
<p>Finland, M. 1931. “SPECIFIC CUTANEOUS REACTIONS AND CIRCULATING ANTIBODIES IN THE COURSE OF LOBAR PNEUMONIA: I. CASES RECEIVING NO SERUM THERAPY.” <em>Journal of Experimental Medicine</em> 54 (5): 637–52. doi:<a href="https://doi.org/10.1084/jem.54.5.637">10.1084/jem.54.5.637</a>.</p>
</div>
<div>
<p>Fireman, Bruce, Steven B Black, Henry R Shinefield, Janelle Lee, Edwin Lewis, and Paula Ray. 2003. “Impact of the pneumococcal conjugate vaccine on otitis media.” 1. 2003/01/25. Vol. 22. The Pediatric infectious disease journal. doi:<a href="https://doi.org/10.1097/00006454-200301000-00006">10.1097/00006454-200301000-00006</a>.</p>
</div>
<div>
<p>Florentzson, Rut, and Caterina Finizia. 2012. “Transmyringeal ventilation tube treatment: a 10-year cohort study.” <em>International Journal of Pediatric Otorhinolaryngology</em> 76 (8). Elsevier Ireland Ltd: 1117–22. doi:<a href="https://doi.org/10.1016/j.ijporl.2012.04.013">10.1016/j.ijporl.2012.04.013</a>.</p>
</div>
<div>
<p>Francis, T, and W S Tillett. 1930. “Cutaneous reactions in pneumonia. The development of antibodies following the intradermal injection of type-specific polysaccharide.” <em>The Journal of Experimental Medicine</em>. doi:<a href="https://doi.org/10.1084/jem.52.4.573">10.1084/jem.52.4.573</a>.</p>
</div>
<div>
<p>Gendrel, D., J. Raymond, F. Moulin, J. L. Iniguez, S. Ravilly, F. Habib, P. Lebon, and G. Kalifa. 1997. “Etiology and response to antibiotic therapy of community-acquired pneumonia in French children.” <em>European Journal of Clinical Microbiology &amp; Infectious Diseases</em> 16 (5): 388–91. doi:<a href="https://doi.org/10.1007/BF01726370">10.1007/BF01726370</a>.</p>
</div>
<div>
<p>Geno, K. Aaron, Gwendolyn L. Gilbert, Joon Young Song, Ian C. Skovsted, Keith P. Klugman, Christopher Jones, Helle B. Konradsen, and Moon H. Nahm. 2015. “Pneumococcal Capsules and Their Types: Past, Present, and Future.” <em>Clinical Microbiology Reviews</em> 28 (3): 871–99. doi:<a href="https://doi.org/10.1128/CMR.00024-15">10.1128/CMR.00024-15</a>.</p>
</div>
<div>
<p>Gilani, Zunera, Yuenting D. Kwong, Orin S. Levine, Maria Deloria-Knoll, J. Anthony G Scott, Katherine L. O’Brien, and Daniel R. Feikin. 2012. “A Literature Review and Survey of Childhood Pneumonia Etiology Studies: 2000–2010.” <em>Clinical Infectious Diseases</em> 54 (suppl_2): S102–S108. doi:<a href="https://doi.org/10.1093/cid/cir1053">10.1093/cid/cir1053</a>.</p>
</div>
<div>
<p>Gisselsson-Solen, Marie. 2017. “Trends in Otitis Media Incidence After Conjugate Pneumococcal Vaccination; A National Observational Study.” <em>The Pediatric Infectious Disease Journal</em> 36 (11): 1. doi:<a href="https://doi.org/10.1097/INF.0000000000001654">10.1097/INF.0000000000001654</a>.</p>
</div>
<div>
<p>Glezen, W. Paul, and Floyd W. Denny. 1973. “Epidemiology of Acute Lower Respiratory Disease in Children.” <em>New England Journal of Medicine</em> 288 (10): 498–505. doi:<a href="https://doi.org/10.1056/NEJM197303082881005">10.1056/NEJM197303082881005</a>.</p>
</div>
<div>
<p>Gouveia, Miguel, Francesca Fiorentino, Gonçalo Jesus, João Costa, and Margarida Borges. 2017. “Cost-effectiveness of the 13-valent Pneumococcal Conjugate Vaccine in Children in Portugal.” <em>The Pediatric Infectious Disease Journal</em> 36 (8): 782–87. doi:<a href="https://doi.org/10.1097/INF.0000000000001587">10.1097/INF.0000000000001587</a>.</p>
</div>
<div>
<p>Gram, Christian. 1884. “Ueber die isolierte Fabung der Schizomyceten in Schnitt und Trockenpraparaten.” <em>Fortschritte Der Medicin</em> 2: 185–89.</p>
</div>
<div>
<p>Gray, Alastair M, Philip M Clarke, Jane L Wolstenholme, and Sarah Wordsworth. 2011. <em>Applied Methods of Cost-effectiveness Analysis in Health Care</em>. New York: Oxford University Press.</p>
</div>
<div>
<p>Gudnason, Thorolfur, Birgir Hrafnkelsson, Brynja Laxdal, and Karl G. Kristinsson. 2013. “Does hygiene intervention at day care centres reduce infectious illnesses in children? An intervention cohort study.” <em>Scandinavian Journal of Infectious Diseases</em> 45 (5): 397–403. doi:<a href="https://doi.org/10.3109/00365548.2012.749424">10.3109/00365548.2012.749424</a>.</p>
</div>
<div>
<p>Hadley, Jack. 2003. “Sicker and Poorer—The Consequences of Being Uninsured: A Review of the Research on the Relationship between Health Insurance, Medical Care Use, Health, Work, and Income.” <em>Medical Care Research and Review</em> 60 (2_suppl): 3S–75S. doi:<a href="https://doi.org/10.1177/1077558703254101">10.1177/1077558703254101</a>.</p>
</div>
<div>
<p>Harrell, Jr., Frank E. 2018. <em>Rms: Regression Modeling Strategies</em>. <a href="https://CRAN.R-project.org/package=rms" class="uri">https://CRAN.R-project.org/package=rms</a>.</p>
</div>
<div>
<p>Heidelberger, M, and O T Avery. 1923. “THE SOLUBLE SPECIFIC SUBSTANCE OF PNEUMOCOCCUS.” <em>The Journal of Experimental Medicine</em>. doi:<a href="https://doi.org/10.1084/jem.40.3.301">10.1084/jem.40.3.301</a>.</p>
</div>
<div>
<p>Herdman, Michael, Amanda Cole, Christopher K Hoyle, Victoria Coles, Stuart Carroll, and Nancy Devlin. 2016. “Sources and Characteristics of Utility Weights for Economic Evaluation of Pediatric Vaccines: A Systematic Review.” <em>Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research</em> 19 (2): 255–66. doi:<a href="https://doi.org/10.1016/j.jval.2015.11.003">10.1016/j.jval.2015.11.003</a>.</p>
</div>
<div>
<p>Hoek, Albert Jan van, Yoon Hong Choi, Caroline Trotter, Elizabeth Miller, and Mark Jit. 2012. “The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England.” <em>Vaccine</em> 30 (50). Elsevier Ltd: 7205–13. doi:<a href="https://doi.org/10.1016/j.vaccine.2012.10.017">10.1016/j.vaccine.2012.10.017</a>.</p>
</div>
<div>
<p>Holubar, Marisa, Maria Christina Stavroulakis, Yvonne Maldonado, John P A Ioannidis, and Despina Contopoulos-Ioannidis. 2017. “Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis.” <em>PLoS ONE</em> 12 (3): 1–22. doi:<a href="https://doi.org/10.1371/journal.pone.0172414">10.1371/journal.pone.0172414</a>.</p>
</div>
<div>
<p>Hoshino, Kazuhiko, Hiroshi Watanabe, Rinya Sugita, Norichika Asoh, Simon Angelo Ntabaguzi, Kiwao Watanabe, Kazunori Oishi, and Tsuyoshi Nagatake. 2002. “High rate of transmission of penicillin-resistant Streptococcus pneumoniae between parents and children.” <em>Journal of Clinical Microbiology</em> 40 (11): 4357–9. doi:<a href="https://doi.org/10.1128/JCM.40.11.4357">10.1128/JCM.40.11.4357</a>.</p>
</div>
<div>
<p>Isaacman, Daniel J, David R Strutton, Edward a Kalpas, Nathalie Horowicz-Mehler, Lee S Stern, Roman Casciano, and Vincent Ciuryla. 2008. “The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.” <em>Clinical Therapeutics</em> 30 (2): 341–57. doi:<a href="https://doi.org/10.1016/j.clinthera.2008.02.003">10.1016/j.clinthera.2008.02.003</a>.</p>
</div>
<div>
<p>Jain, Seema, Derek J. Williams, Sandra R. Arnold, Krow Ampofo, Anna M. Bramley, Carrie Reed, Chris Stockmann, et al. 2015. “Community-Acquired Pneumonia Requiring Hospitalization among U.S. Children.” <em>New England Journal of Medicine</em> 372: 835–45. doi:<a href="https://doi.org/10.1056/NEJMoa1405870">10.1056/NEJMoa1405870</a>.</p>
</div>
<div>
<p>Kaur, Ravinder, Matthew Morris, and Michael E. Pichichero. 2017. “Epidemiology of Acute Otitis Media in the Postpneumococcal Conjugate Vaccine Era.” <em>Pediatrics</em> 140 (3): e20170181. doi:<a href="https://doi.org/10.1542/peds.2017-0181">10.1542/peds.2017-0181</a>.</p>
</div>
<div>
<p>Keyhani, Salomeh, Lawrence C Kleinman, Michael Rothschild, Joseph M Bernstein, Rebecca Anderson, and Mark Chassin. 2008. “Overuse of tympanostomy tubes in New York metropolitan area: evidence from five hospital cohort.” <em>BMJ (Clinical Research Ed.)</em> 337 (5). British Medical Journal Publishing Group: a1607. doi:<a href="https://doi.org/10.1136/bmj.a1607">10.1136/bmj.a1607</a>.</p>
</div>
<div>
<p>Kilpi, T, Heidi Ahman, J Jokinen, K S Lankinen, A Palmu, H Savolainen, M Gronholm, et al. 2003. “Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate v.” <em>Clin Infect Dis</em> 37 (9): 1155–64. doi:<a href="https://doi.org/10.1086/378744">10.1086/378744</a>.</p>
</div>
<div>
<p>Kilpi, T.M., J. Jokinen, T. Puumalainen, H. Nieminen, E. Ruokokoski, H. Rinta-Kokko, M. Traskine, et al. 2018. “Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against pneumonia in children: A cluster-randomised trial.” <em>Vaccine</em> 36 (39). The Authors: 5891–5901. doi:<a href="https://doi.org/10.1016/j.vaccine.2018.08.020">10.1016/j.vaccine.2018.08.020</a>.</p>
</div>
<div>
<p>Kim, Su Jin, Ji Hyun Chung, Ho Min Kang, and Seung Geun Yeo. 2013. “Clinical bacteriology of recurrent otitis media with effusion.” <em>Acta Oto-Laryngologica</em> 133 (11). Taylor &amp; Francis: 1133–41. doi:<a href="https://doi.org/10.3109/00016489.2013.816442">10.3109/00016489.2013.816442</a>.</p>
</div>
<div>
<p>Kirkwood, BR, and JAC Sterne. 2003. <em>Essential medical statistics</em>. Edited by Fiona Goodgame. 2nd ed. Oxford: Blackwell Science. doi:<a href="https://doi.org/10.1002/sim.1961">10.1002/sim.1961</a>.</p>
</div>
<div>
<p>Klok, Rogier M, Rose-Marie Lindkvist, Mats Ekelund, Raymond a Farkouh, and David R Strutton. 2013. “Cost-Effectiveness of a 10- Versus 13-Valent Pneumococcal Conjugate Vaccine in Denmark and Sweden.” <em>Clinical Therapeutics</em> 35 (2). Elsevier Inc.: 119–34. doi:<a href="https://doi.org/10.1016/j.clinthera.2012.12.006">10.1016/j.clinthera.2012.12.006</a>.</p>
</div>
<div>
<p>Knerer, Gerhart, Afisi Ismaila, and David Pearce. 2012. “Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise.” <em>Journal of Medical Economics</em> 15 (1): 61–76. doi:<a href="https://doi.org/10.3111/13696998.2011.622323">10.3111/13696998.2011.622323</a>.</p>
</div>
<div>
<p>Kuhlmann, Alexander, and J-Matthias Graf von der Schulenburg. 2017. “Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.” <em>The European Journal of Health Economics</em> 18 (3). Springer Berlin Heidelberg: 273–92. doi:<a href="https://doi.org/10.1007/s10198-016-0770-9">10.1007/s10198-016-0770-9</a>.</p>
</div>
<div>
<p>Lau, Wallis C Y, Macey Murray, Aisha El-Turki, Sonia Saxena, Shamez Ladhani, Paul Long, Mike Sharland, Ian C K Wong, and Yingfen Hsia. 2015. “Impact of pneumococcal conjugate vaccines on childhood otitis media in the United Kingdom.” <em>Vaccine</em> 33 (39): 5072–9. doi:<a href="https://doi.org/10.1016/j.vaccine.2015.08.022">10.1016/j.vaccine.2015.08.022</a>.</p>
</div>
<div>
<p>Le Polain de Waroux, Olivier, Stefan Flasche, David Prieto-Merino, and W John Edmunds. 2014. “Age-Dependent Prevalence of Nasopharyngeal Carriage of Streptococcus pneumoniae before Conjugate Vaccine Introduction: A Prediction Model Based on a Meta-Analysis.” Edited by Hiroshi Nishiura. <em>PLoS ONE</em> 9 (1): e86136. doi:<a href="https://doi.org/10.1371/journal.pone.0086136">10.1371/journal.pone.0086136</a>.</p>
</div>
<div>
<p>Legood, Rosa, Pietro G Coen, Kyle Knox, Russell M Viner, Haitham El Bashir, Deborah Christie, Bharat C Patel, and Robert Booy. 2009. “Health related quality of life in survivors of pneumococcal meningitis.” <em>Acta Paediatrica</em> 98 (3): 543–47. doi:<a href="https://doi.org/10.1111/j.1651-2227.2008.01136.x">10.1111/j.1651-2227.2008.01136.x</a>.</p>
</div>
<div>
<p>Leino, Tuija, Kari Auranen, Jukka Jokinen, Maija Leinonen, Päivi Tervonen, and Aino K. Takala. 2001. “Pneumococcal carriage in children during their first two years: important role of family exposure.” <em>The Pediatric Infectious Disease Journal</em> 20 (11): 1022–7. doi:<a href="https://doi.org/10.1097/00006454-200111000-00004">10.1097/00006454-200111000-00004</a>.</p>
</div>
<div>
<p>Levine, Orin S., Katherine L. O’Brien, Maria Deloria-Knoll, David R. Murdoch, Daniel R. Feikin, A. N. DeLuca, Amanda J. Driscoll, et al. 2012. “The Pneumonia Etiology Research for Child Health Project: A 21st Century Childhood Pneumonia Etiology Study.” <em>Clinical Infectious Diseases</em> 54 (suppl 2): S93–S101. doi:<a href="https://doi.org/10.1093/cid/cir1052">10.1093/cid/cir1052</a>.</p>
</div>
<div>
<p>Liese, J. G., S. A. Silfverdal, C. Giaquinto, A. Carmona, J. H. Larcombe, J. Garcia-Sicilia, A. Fuat, et al. 2014. “Incidence and clinical presentation of acute otitis media in children aged &lt;6 years in European medical practices.” <em>Epidemiology and Infection</em> 142 (8). Cambridge University Press: 1778–88. doi:<a href="https://doi.org/10.1017/S0950268813002744">10.1017/S0950268813002744</a>.</p>
</div>
<div>
<p>Lin, D. Y., and L. J. Wei. 1989. “The Robust Inference for the Cox Proportional Hazards Model.” <em>Journal of the American Statistical Association</em> 84 (408): 1074–8. doi:<a href="https://doi.org/10.1080/01621459.1989.10478874">10.1080/01621459.1989.10478874</a>.</p>
</div>
<div>
<p>Lister, Frederick Spencer. 1916. “An experimental study of prophylactic inoculation against pneumococcal infection in the rabbit and in man.” <em>Publication of the South African Institute of Medical Research</em> 8: 231–87.</p>
</div>
<div>
<p>Lister, Frederick Spencer, and D Ordman. 1936. “The Epidemiology of Pneumonia on the Witwatersrand Goldfields and the Prevention of Pneumonia and Other Allied Acute Respiratory Diseases in Native Labourers in South Africa by Means of Vaccine.” <em>Journal of the American Medical Association</em> 106 (9): 733. doi:<a href="https://doi.org/10.1001/jama.1936.02770090069032">10.1001/jama.1936.02770090069032</a>.</p>
</div>
<div>
<p>Loo, Jennifer D, Laura Conklin, Katherine E Fleming-Dutra, Maria Deloria Knoll, Daniel E Park, Jennifer Kirk, David Goldblatt, Katherine L O’Brien, and Cynthia G Whitney. 2014. “Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization.” <em>The Pediatric Infectious Disease Journal</em> 33 Suppl 2 (1). Wolters Kluwer Health: S161–71. doi:<a href="https://doi.org/10.1097/INF.0000000000000084">10.1097/INF.0000000000000084</a>.</p>
</div>
<div>
<p>Mackenzie, Grant. 2016. “The definition and classification of pneumonia.” <em>Pneumonia</em> 8 (1). Pneumonia: 14. doi:<a href="https://doi.org/10.1186/s41479-016-0012-z">10.1186/s41479-016-0012-z</a>.</p>
</div>
<div>
<p>Macleod, C M, Richard G Hodges, Michael Heidelberger, and W G Bernhard. 1945. “PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES.” <em>The Journal of Experimental Medicine</em> 82 (6): 445–65. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19871511 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC2135567" class="uri">http://www.ncbi.nlm.nih.gov/pubmed/19871511 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC2135567</a>.</p>
</div>
<div>
<p>Maddigan, Sheri L., David H. Feeny, and Jeffrey A. Johnson. 2005. “Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey.” <em>Quality of Life Research</em> 14 (5): 1311–20. doi:<a href="https://doi.org/10.1007/s11136-004-6640-4">10.1007/s11136-004-6640-4</a>.</p>
</div>
<div>
<p>Madhi, Shabir a, Philippe De Wals, Carlos G Grijalva, Keith Grimwood, Ronald Grossman, Naruhiko Ishiwada, Ping-Ing Lee, et al. 2012. “The Burden of Childhood Pneumonia in the Developed World.” <em>The Pediatric Infectious Disease Journal</em> 32 (3): 1. doi:<a href="https://doi.org/10.1097/INF.0b013e3182784b26">10.1097/INF.0b013e3182784b26</a>.</p>
</div>
<div>
<p>Marom, Tal, Alai Tan, Gregg S. Wilkinson, Karen S. Pierson, Jean L. Freeman, and Tasnee Chonmaitree. 2014. “Trends in otitis media-related health care use in the United States, 2001-2011.” <em>JAMA Pediatrics</em> 168 (1). American Medical Association: 68–75. doi:<a href="https://doi.org/10.1001/jamapediatrics.2013.3924">10.1001/jamapediatrics.2013.3924</a>.</p>
</div>
<div>
<p>Mauskopf, Josephine, Baudouin Standaert, Mark P. Connolly, Anthony J. Culyer, Louis P. Garrison, Raymond Hutubessy, Mark Jit, Richard Pitman, Paul Revill, and Johan L. Severens. 2018. “Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report.” <em>Value in Health</em> 21 (10). Elsevier Inc.: 1133–49. doi:<a href="https://doi.org/10.1016/j.jval.2018.08.005">10.1016/j.jval.2018.08.005</a>.</p>
</div>
<div>
<p>Maynard, G D. 1913. “An enquiry into the etiology, manifestations and prevention of pneumonia amongst natives on the Rand recruited from tropical areas.” <em>Public South Afr Inst Med Res</em> 1 (0): 1–101.</p>
</div>
<div>
<p>Mäkelä, P H, M Leinonen, J Pukander, and P Karma. 1981. “A study of the pneumococcal vaccine in prevention of clinically acute atttacks of recurrent otitis media.” <em>Reviews of Infectious Diseases</em> 3 Suppl: S124–32. <a href="http://www.ncbi.nlm.nih.gov/pubmed/6974386" class="uri">http://www.ncbi.nlm.nih.gov/pubmed/6974386</a>.</p>
</div>
<div>
<p>Melegaro, A, and W.J. Edmunds. 2004. “Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.” <em>Vaccine</em> 22 (31-32): 4203–14. doi:<a href="https://doi.org/10.1016/j.vaccine.2004.05.003">10.1016/j.vaccine.2004.05.003</a>.</p>
</div>
<div>
<p>MELEGARO, A., N. J. GAY, and G. F. MEDLEY. 2004. “Estimating the transmission parameters of pneumococcal carriage in households.” <em>Epidemiology and Infection</em> 132 (3): 433–41. doi:<a href="https://doi.org/10.1017/S0950268804001980">10.1017/S0950268804001980</a>.</p>
</div>
<div>
<p>Morrow, Adrienne, Philippe De Wals, Geneviève Petit, Maryse Guay, and Lonny James Erickson. 2007. “The Burden of Pneumococcal Disease in the Canadian Population Before Routine Use of the Seven-Valent Pneumococcal Conjugate Vaccine.” <em>Canadian Journal of Infectious Diseases and Medical Microbiology</em> 18 (2): 121–27. doi:<a href="https://doi.org/10.1155/2007/713576">10.1155/2007/713576</a>.</p>
</div>
<div>
<p>Mosser, Jonathan F., Lindsay R. Grant, Eugene V. Millar, Robert C. Weatherholtz, Delois M. Jackson, Bernard Beall, Mariddie J. Craig, Raymond Reid, Mathuram Santosham, and Katherine L. O’Brien. 2014. “Nasopharyngeal carriage and transmission of Streptococcus pneumoniae in American Indian households after a decade of pneumococcal conjugate vaccine use.” <em>PLoS ONE</em> 9 (1): 3–10. doi:<a href="https://doi.org/10.1371/journal.pone.0079578">10.1371/journal.pone.0079578</a>.</p>
</div>
<div>
<p>Newall, A.T., J.F. Reyes, P. McIntyre, R. Menzies, P. Beutels, and J.G. Wood. 2016. “Retrospective economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Australia: Uncertain herd impact on pneumonia critical.” <em>Vaccine</em> 34 (3). Elsevier Ltd: 320–27. doi:<a href="https://doi.org/10.1016/j.vaccine.2015.11.053">10.1016/j.vaccine.2015.11.053</a>.</p>
</div>
<div>
<p>Newall, Anthony T., Prudence Creighton, David J. Philp, James G. Wood, and C. Raina MacIntyre. 2011. “The potential cost-effectiveness of infant pneumococcal vaccines in Australia.” <em>Vaccine</em> 29: 8077–85. doi:<a href="https://doi.org/10.1016/j.vaccine.2011.08.050">10.1016/j.vaccine.2011.08.050</a>.</p>
</div>
<div>
<p>Ngo, Chinh C., Helen M. Massa, Ruth B. Thornton, and Allan W. Cripps. 2016. “Predominant Bacteria Detected from the Middle Ear Fluid of Children Experiencing Otitis Media: A Systematic Review.” Edited by Sean Reid. <em>PloS One</em> 11 (3): e0150949. doi:<a href="https://doi.org/10.1371/journal.pone.0150949">10.1371/journal.pone.0150949</a>.</p>
</div>
<div>
<p>Nicholls, Thomas Rodger, Amanda Jane Leach, and Peter Stanley Morris. 2016. “The short-term impact of each primary dose of pneumococcal conjugate vaccine on nasopharyngeal carriage: Systematic review and meta-analyses of randomised controlled trials.” <em>Vaccine</em> 34 (6). Elsevier Ltd: 703–13. doi:<a href="https://doi.org/10.1016/j.vaccine.2015.12.048">10.1016/j.vaccine.2015.12.048</a>.</p>
</div>
<div>
<p>Oostenbrink, Rianne, Henriëtte A Moll, and Marie-Louise Essink-Bot. 2002. “The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis.” <em>Journal of Clinical Epidemiology</em> 55 (8): 791–99. doi:<a href="https://doi.org/10.1016/S0895-4356(02)00448-1">10.1016/S0895-4356(02)00448-1</a>.</p>
</div>
<div>
<p>O’Brien, Katherine L, Lawrence H Moulton, Raymond Reid, Robert Weatherholtz, Jane Oski, Laura Brown, Gaurav Kumar, et al. 2003. “Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial.” <em>Lancet</em> 362 (9381): 355–61. doi:<a href="https://doi.org/10.1016/S0140-6736(03)14022-6">10.1016/S0140-6736(03)14022-6</a>.</p>
</div>
<div>
<p>O’Brien, Katherine L., Angeline B David, Aruna Chandran, Lawrence H Moulton, Raymond Reid, Robert Weatherholtz, and Mathuram Santosham. 2008. “RANDOMIZED, CONTROLLED TRIAL EFFICACY OF PNEUMOCOCCAL CONJUGATE VACCINE AGAINST OTITIS MEDIA AMONG NAVAJO AND WHITE MOUNTAIN APACHE INFANTS.” <em>The Pediatric Infectious Disease Journal</em> 27 (1): 71–73. doi:<a href="https://doi.org/10.1097/INF.0b013e318159228f">10.1097/INF.0b013e318159228f</a>.</p>
</div>
<div>
<p>O’Brien, Megan A, Lisa A Prosser, Jack L Paradise, G Thomas Ray, Martin Kulldorff, Marcia Kurs-Lasky, Virginia L Hinrichsen, Jyotsna Mehta, D Kathleen Colborn, and Tracy A Lieu. 2009. “New vaccines against otitis media: projected benefits and cost-effectiveness.” <em>Pediatrics</em> 123 (6): 1452–63. doi:<a href="https://doi.org/10.1542/peds.2008-1482">10.1542/peds.2008-1482</a>.</p>
</div>
<div>
<p>PAISLEY, JOHN W., BRIAN A. LAUER, KENNETH MCINTOSH, MARY P. GLODE, JULIUS SCHACHTER, and ACAROL RUMACK. 1984. “Pathogens associated with acute lower respiratory tract infection in young children.” <em>The Pediatric Infectious Disease Journal</em> 3 (1): 14–19. doi:<a href="https://doi.org/10.1097/00006454-198401000-00005">10.1097/00006454-198401000-00005</a>.</p>
</div>
<div>
<p>Palmu, Arto A I, Jouko Verho, Jukka Jokinen, Pekka Karma, and Terhi M Kilpi. 2004. “The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children.” <em>The Pediatric Infectious Disease Journal</em> 23 (8): 732–38. doi:<a href="https://doi.org/10.1097/01.inf.0000133049.30299.5d">10.1097/01.inf.0000133049.30299.5d</a>.</p>
</div>
<div>
<p>Palmu, Arto A, Jukka Jokinen, Dorota Borys, Heta Nieminen, Esa Ruokokoski, Lotta Siira, Taneli Puumalainen, et al. 2013. “Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.” <em>Lancet</em> 381 (9862): 214–22. doi:<a href="https://doi.org/10.1016/s0140-6736(12)61854-6">10.1016/s0140-6736(12)61854-6</a>.</p>
</div>
<div>
<p>Palmu, Arto, Jukka Jokinen, Heta Nieminen, Hanna Rinta-Kokko, Esa Ruokokoski, Taneli Puumalainen, Magali Traskine, et al. 2015. “Effectiveness of the 10-Valent Pneumococcal Conjugate Vaccine Against Tympanostomy Tube Placements in a Cluster-Randomized Trial.” <em>The Pediatric Infectious Disease Journal</em> 34 (11): 1230–5. doi:<a href="https://doi.org/http://dx.doi.org/10.1097/INF.0000000000000857">http://dx.doi.org/10.1097/INF.0000000000000857</a>.</p>
</div>
<div>
<p>Parker, Devin M., Laura Schang, Jared R. Wasserman, Weston D. Viles, Gwyn Bevan, and David C. Goodman. 2016. “Variation in Utilization and Need for Tympanostomy Tubes across England and New England.” <em>The Journal of Pediatrics</em> 179 (December). Elsevier Inc.: 178–184.e4. doi:<a href="https://doi.org/10.1016/j.jpeds.2016.08.093">10.1016/j.jpeds.2016.08.093</a>.</p>
</div>
<div>
<p>Pasteur, Louis. 1881. “Note sur la maladie nouvelle provoquee par la salive d’un enfant mort de la rage.” 10. Vol. 2. Paris: I’Academie de Medicine. <a href="https://gallica.bnf.fr/ark:/12148/bpt6k408671n" class="uri">https://gallica.bnf.fr/ark:/12148/bpt6k408671n</a>.</p>
</div>
<div>
<p>Petrou, Stavros, and Emil Kupek. 2009. “Estimating preference-based health utilities index mark 3 utility scores for childhood conditions in England and Scotland.” <em>Medical Decision Making : An International Journal of the Society for Medical Decision Making</em> 29 (3): 291–303. doi:<a href="https://doi.org/10.1177/0272989X08327398">10.1177/0272989X08327398</a>.</p>
</div>
<div>
<p>Pichichero, Michael E., Janet R. Casey, Alejandro Hoberman, and Richard Schwartz. 2008. “Pathogens causing recurrent and difficult-to-treat acute otitis media, 2003-2006.” <em>Clinical Pediatrics</em> 47 (9): 901–6. doi:<a href="https://doi.org/10.1177/0009922808319966">10.1177/0009922808319966</a>.</p>
</div>
<div>
<p>Pitman, Richard, David Fisman, Gregory S. Zaric, Maarten Postma, Mirjam Kretzschmar, John Edmunds, and Marc Brisson. 2012. “Dynamic Transmission Modeling.” <em>Medical Decision Making</em> 32 (5): 712–21. doi:<a href="https://doi.org/10.1177/0272989X12454578">10.1177/0272989X12454578</a>.</p>
</div>
<div>
<p>Prosser, Lisa A, G Thomas Ray, M. O’Brien, Ken Kleinman, Jeanne Santoli, and Tracy A Lieu. 2004. “Preferences and Willingness to Pay for Health States Prevented by Pneumococcal Conjugate Vaccine.” <em>PEDIATRICS</em> 113 (2): 283–90. doi:<a href="https://doi.org/10.1542/peds.113.2.283">10.1542/peds.113.2.283</a>.</p>
</div>
<div>
<p>Prymula, Roman, Pascal Peeters, Viktor Chrobok, Pavla Kriz, Elena Novakova, Eva Kaliskova, Igor Kohl, et al. 2006. “Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: A randomised double-blind efficacy study.” <em>Lancet</em> 367 (9512): 740–48. doi:<a href="https://doi.org/10.1016/S0140-6736(06)68304-9">10.1016/S0140-6736(06)68304-9</a>.</p>
</div>
<div>
<p>Pumarola, Felix, Josep Marès, Isabel Losada, Isabel Minguella, Fernando Moraga, David Tarragó, Ulla Aguilera, et al. 2013. “Microbiology of bacteria causing recurrent acute otitis media (AOM) and AOM treatment failure in young children in Spain: Shifting pathogens in the post-pneumococcal conjugate vaccination era.” <em>International Journal of Pediatric Otorhinolaryngology</em> 77 (8): 1231–6. doi:<a href="https://doi.org/10.1016/j.ijporl.2013.04.002">10.1016/j.ijporl.2013.04.002</a>.</p>
</div>
<div>
<p>R Core Team. 2018. <em>R: A Language and Environment for Statistical Computing</em>. Vienna, Austria: R Foundation for Statistical Computing. <a href="https://www.R-project.org/" class="uri">https://www.R-project.org/</a>.</p>
</div>
<div>
<p>Ramakrishnan, Kalyanakrishnan, Rhonda A Sparks, and Wayne E Berryhill. 2007. “Diagnosis and treatment of otitis media.” <em>American Family Physician</em> 76 (11): 1650–8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18092706" class="uri">http://www.ncbi.nlm.nih.gov/pubmed/18092706</a>.</p>
</div>
<div>
<p>Robberstad, Bjarne, Carl R. Frostad, Per E. Akselsen, Kari J. Kværner, and Aud K H Berstad. 2011. “Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.” <em>Vaccine</em> 29: 8564–74. doi:<a href="https://doi.org/10.1016/j.vaccine.2011.09.025">10.1016/j.vaccine.2011.09.025</a>.</p>
</div>
<div>
<p>Rodrigues, C. M. C., and H. Groves. 2017. “Community-Acquired Pneumonia in Children: the Challenges of Microbiological Diagnosis.” Edited by Colleen Suzanne Kraft. <em>Journal of Clinical Microbiology</em> 56 (3): JCM.01318–17. doi:<a href="https://doi.org/10.1128/JCM.01318-17">10.1128/JCM.01318-17</a>.</p>
</div>
<div>
<p>Rozenbaum, M. H., P. Pechlivanoglou, T. S. Werf, J. R. Lo-Ten-Foe, M. J. Postma, and E. Hak. 2013. “The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis.” <em>European Journal of Clinical Microbiology &amp; Infectious Diseases</em> 32 (3): 305–16. doi:<a href="https://doi.org/10.1007/s10096-012-1778-4">10.1007/s10096-012-1778-4</a>.</p>
</div>
<div>
<p>Rozenbaum, Mark H, Elisabeth a M Sanders, Albert Jan van Hoek, Angelique G S C Jansen, Arie van der Ende, Germie van den Dobbelsteen, Gerwin D Rodenburg, Eelko Hak, and Maarten J Postma. 2010. “Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.” <em>BMJ</em> 340 (jun02 1): c2509–c2509. doi:<a href="https://doi.org/10.1136/bmj.c2509">10.1136/bmj.c2509</a>.</p>
</div>
<div>
<p>Rubin, Jaime L., Lisa J. McGarry, David R. Strutton, Keith P. Klugman, Stephen I. Pelton, Kristen E. Gilmore, and Milton C. Weinstein. 2010. “Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States.” <em>Vaccine</em> 28 (48). Elsevier Ltd: 7634–43. doi:<a href="https://doi.org/10.1016/j.vaccine.2010.09.049">10.1016/j.vaccine.2010.09.049</a>.</p>
</div>
<div>
<p>Ruuskanen, O., H. Nohynek, T. Ziegler, R. Capeding, H. Rikalainen, P. Huovinen, and M. Leinonen. 1992. “Pneumonia in childhood: Etiology and response to antimicrobial therapy.” <em>European Journal of Clinical Microbiology &amp; Infectious Diseases</em> 11 (3): 217–23. doi:<a href="https://doi.org/10.1007/BF02098083">10.1007/BF02098083</a>.</p>
</div>
<div>
<p>Sanders, Gillian D., Peter J. Neumann, Anirban Basu, Dan W. Brock, David Feeny, Murray Krahn, Karen M. Kuntz, et al. 2016. “Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses.” <em>JAMA</em> 316 (10): 1093. doi:<a href="https://doi.org/10.1001/jama.2016.12195">10.1001/jama.2016.12195</a>.</p>
</div>
<div>
<p>Saokaew, Surasak, Ajaree Rayanakorn, David Bin-Chia Wu, and Nathorn Chaiyakunapruk. 2016. “Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review.” <em>PharmacoEconomics</em> 34 (12). Springer International Publishing: 1211–25. doi:<a href="https://doi.org/10.1007/s40273-016-0439-3">10.1007/s40273-016-0439-3</a>.</p>
</div>
<div>
<p>Schiemann, O., and W. Casper. 1927. “Sind die spezifisch pracipitablen Substanzen der 3 Pneumokokkentypen Haptene?” <em>Zeitschrift Fur Hygiene Und Infektionskrankheiten</em>. doi:<a href="https://doi.org/10.1007/BF02176583">10.1007/BF02176583</a>.</p>
</div>
<div>
<p>Severens, Johan L., and Richard J. Milne. 2004. “Discounting health outcomes in economic evaluation: the ongoing debate.” <em>Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research</em> 7 (4): 397–401. doi:<a href="https://doi.org/10.1111/j.1524-4733.2004.74002.x">10.1111/j.1524-4733.2004.74002.x</a>.</p>
</div>
<div>
<p>Shioda, Kayoko, Cynthia Schuck-Paim, Robert J. Taylor, Roger Lustig, Lone Simonsen, Joshua L Warren, and Daniel M Weinberger. 2018. “Challenges in estimating the impact of vaccination with sparse data.” <em>Epidemiology (Cambridge, Mass.)</em> 4 (5): 1. doi:<a href="https://doi.org/10.1097/EDE.0000000000000938">10.1097/EDE.0000000000000938</a>.</p>
</div>
<div>
<p>Sloyer, John L, John H Ploussard, and Virgil M Howie. 1981. “Efficacy of pneumococcal polysaccharide vaccine in preventing acute otitis media in infants in Huntsville, Alabama.” <em>Reviews of Infectious Diseases</em> 3 Suppl: S119–23. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7280444" class="uri">http://www.ncbi.nlm.nih.gov/pubmed/7280444</a>.</p>
</div>
<div>
<p>Smit, Pieter. 1977. “Protective Efficacy of Pneumococcal Polysaccharide Vaccines.” <em>JAMA: The Journal of the American Medical Association</em> 238 (24): 2613. doi:<a href="https://doi.org/10.1001/jama.1977.03280250039019">10.1001/jama.1977.03280250039019</a>.</p>
</div>
<div>
<p>Smolderen, Kim G. 2010. “Health Care Insurance, Financial Concerns in Accessing Care, and Delays to Hospital Presentation in Acute Myocardial Infarction.” <em>JAMA</em> 303 (14). American Medical Association: 1392. doi:<a href="https://doi.org/10.1001/jama.2010.409">10.1001/jama.2010.409</a>.</p>
</div>
<div>
<p>Sonsuwan, Nuntigar, Patcharin Watcharinyanon, and Kittisak Sawanyawisuth. 2016. “What are the leading causative pathogens in acute otitis media with tympanic membrane perforation?” <em>International Journal of Pediatric Otorhinolaryngology</em> 90 (November). Elsevier Ltd: 20–22. doi:<a href="https://doi.org/10.1016/j.ijporl.2016.08.021">10.1016/j.ijporl.2016.08.021</a>.</p>
</div>
<div>
<p>Spilsbury, Katrina, Abdul Latif Kadhim, James B Semmens, Francis J Lannigan, Spilsbury K., Kadhim A.L., Semmens J.B., et al. 2006. “Decreasing rates of middle ear surgery in Western Australian children.” <em>Archives of Otolaryngology - Head and Neck Surgery</em> 132 (11): 1216–20. doi:<a href="https://doi.org/10.1001/archotol.132.11.1216">10.1001/archotol.132.11.1216</a>.</p>
</div>
<div>
<p>Sternberg, G M. 1882. “A fatal form of septicemia in the rabbit produced by subcutaneous injection of human saliva.” Washington: National Board of Health; U.S. Government Printing Office. <a href="https://books.google.is/books?id=YojXubzmx3sC{\&amp;}printsec=frontcover{\&amp;}hl=is{\#}v=onepage{\&amp;}q{\&amp;}f=false" class="uri">https://books.google.is/books?id=YojXubzmx3sC{\&amp;}printsec=frontcover{\&amp;}hl=is{\#}v=onepage{\&amp;}q{\&amp;}f=false</a>.</p>
</div>
<div>
<p>Stevenson, Mark, Telmo Nunes, Cord Heuer, Jonathon Marshall, Javier Sanchez, Ron Thornton, Jeno Reiczigel, Jim Robison-Cox, Paola Sebastiani, and Peter Solymos. 2017. <em>EpiR: Tools for the Analysis of Epidemiological Data</em>. <a href="https://CRAN.R-project.org/package=epiR" class="uri">https://CRAN.R-project.org/package=epiR</a>.</p>
</div>
<div>
<p>Strutton, David R, Raymond a Farkouh, Stephanie R Earnshaw, Sharon Hwang, Ulrike Theidel, Stathis Kontodimas, Rogier Klok, and Sotiria Papanicolaou. 2012. “Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.” <em>Journal of Infection</em> 64 (1). Elsevier Ltd: 54–67. doi:<a href="https://doi.org/10.1016/j.jinf.2011.10.015">10.1016/j.jinf.2011.10.015</a>.</p>
</div>
<div>
<p>Talbird, Sandra E, Thomas N Taylor, Stefanie Knoll, Carl Richard Frostad, and Sebastián García Martí. 2010. “Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries.” <em>Vaccine</em> 28 Suppl 6 (November). Elsevier Ltd: G23–9. doi:<a href="https://doi.org/10.1016/j.vaccine.2010.06.016">10.1016/j.vaccine.2010.06.016</a>.</p>
</div>
<div>
<p>Teele, D W, J O Klein, and B Rosner. 1989. “Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study.” <em>The Journal of Infectious Diseases</em> 160 (1): 83–94. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2732519" class="uri">http://www.ncbi.nlm.nih.gov/pubmed/2732519</a>.</p>
</div>
<div>
<p>Therneau, Terry M. 2018. <em>Survival: Survival Analysis</em>. <a href="https://CRAN.R-project.org/package=survival" class="uri">https://CRAN.R-project.org/package=survival</a>.</p>
</div>
<div>
<p>Tillett, W S, M J Cambier, and J E McCormack. 1944. “The Treatment of Lobar Pneumonia and Pneumococcal Empyema with Penicillin.” <em>Bulletin of the New York Academy of Medicine</em> 20 (3): 142–78. doi:<a href="https://doi.org/10.7326/0003-4819-60-5-759">10.7326/0003-4819-60-5-759</a>.</p>
</div>
<div>
<p>Tregnaghi, Miguel W. Marcelo, Xavier Sáez-Llorens, Pio López, Hector Abate, Enrique Smith, Adriana Pósleman, Arlene Calvo, et al. 2014. “Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.” Edited by Elizabeth Miller. <em>PLoS Medicine</em> 11 (6). Public Library of Science: e1001657. doi:<a href="https://doi.org/10.1371/journal.pmed.1001657">10.1371/journal.pmed.1001657</a>.</p>
</div>
<div>
<p>Troeger, Christopher, Brigette F Blacker, Ibrahim A Khalil, Puja C Rao, Shujin Cao, Stephanie RM Zimsen, Samuel B Albertson, et al. 2018. “Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016.” <em>The Lancet Infectious Diseases</em> 3099 (18): 1–20. doi:<a href="https://doi.org/10.1016/S1473-3099(18)30362-1">10.1016/S1473-3099(18)30362-1</a>.</p>
</div>
<div>
<p>Tuomanen, Elaine I., Robert Austrian, and H. Robert Masure. 1995. “Pathogenesis of Pneumococcal Infection.” Edited by Franklin H. Epstein. <em>New England Journal of Medicine</em> 332 (19): 1280–4. doi:<a href="https://doi.org/10.1056/NEJM199505113321907">10.1056/NEJM199505113321907</a>.</p>
</div>
<div>
<p>Van Dyke, Melissa K., Jean-Yves Pirçon, Robert Cohen, Shabir A. Madhi, Andrés Rosenblüt, Mercedes Macias Parra, Khalid Al-Mazrou, et al. 2017. “Etiology of Acute Otitis Media in Children Less Than 5 Years of Age.” <em>The Pediatric Infectious Disease Journal</em> 36 (3): 274–81. doi:<a href="https://doi.org/10.1097/INF.0000000000001420">10.1097/INF.0000000000001420</a>.</p>
</div>
<div>
<p>VanderWeele, Tyler J., and Peng Ding. 2017. “Sensitivity Analysis in Observational Research: Introducing the E-Value.” <em>Annals of Internal Medicine</em> 167 (4): 268–74. doi:<a href="https://doi.org/10.7326/M16-2607">10.7326/M16-2607</a>.</p>
</div>
<div>
<p>Venekamp, Roderick P, Paul Mick, Anne GM Schilder, and Desmond A Nunez. 2018. “Grommets (ventilation tubes) for recurrent acute otitis media in children.” <em>Cochrane Database of Systematic Reviews</em> (4):CD0047 (4): CD004741. doi:<a href="https://doi.org/10.1002/14651858.CD012017.pub2">10.1002/14651858.CD012017.pub2</a>.</p>
</div>
<div>
<p>Vooren, K van de, S Duranti, A Curto, and L Garattini. 2014. “Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies.” <em>Pharmacoeconomics</em> 32: 29–45. doi:<a href="https://doi.org/10.1007/s40273-013-0113-y">10.1007/s40273-013-0113-y</a>.</p>
</div>
<div>
<p>Waight, Pauline A., Nicholas J. Andrews, Shamez N. Ladhani, Carmen L. Sheppard, Mary P.E. E Slack, and Elizabeth Miller. 2015. “Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: An observational cohort study.” <em>The Lancet Infectious Diseases</em> 15 (5): 535–43. doi:<a href="https://doi.org/10.1016/S1473-3099(15)70044-7">10.1016/S1473-3099(15)70044-7</a>.</p>
</div>
<div>
<p>Walker, Damian G, Raymond Hutubessy, and Philippe Beutels. 2010. “WHO Guide for standardisation of economic evaluations of immunization programmes.” <em>Vaccine</em> 28 (11). Elsevier Ltd: 2356–9. doi:<a href="https://doi.org/10.1016/j.vaccine.2009.06.035">10.1016/j.vaccine.2009.06.035</a>.</p>
</div>
<div>
<p>Wasserman, Matt, Heather L. Sings, Dylan Jones, Sarah Pugh, Margaret Moffatt, and Raymond Farkouh. 2018. “Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine.” <em>Expert Review of Vaccines</em> 17 (1). Taylor &amp; Francis: 71–78. doi:<a href="https://doi.org/10.1080/14760584.2018.1409116">10.1080/14760584.2018.1409116</a>.</p>
</div>
<div>
<p>Watson, David A, Daniel M Musher, James W Jacobson, and Jan Verhoef. 1993. “A Brief History of the Pneumococcus in Biomedical Research: A Panoply of Scientific Discovery Description of the Organism and Demonstration of Its Virulence.” <em>Clinical Infectious Diseases</em> 17: 913–24. doi:<a href="https://doi.org/10.1093/clinids/17.5.913">10.1093/clinids/17.5.913</a>.</p>
</div>
<div>
<p>Weichselbaum, A. 1886. “Ueber die Aetiologie der acuten Lungen-und Rippenfellentzundungen.” <em>Medizinische Jahrbücher.</em>, 483–554.</p>
</div>
<div>
<p>Whitney, C G, T Pilishvili, Monica M Farley, W Schaffner, Allen S Craig, R Lynfield, A C Nyquist, et al. 2006. “Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study.” <em>Lancet</em> 368: 1495–1502. doi:<a href="https://doi.org/S0140-6736(06)69637-2 [pii]\r10.1016/S0140-6736(06)69637-2">S0140-6736(06)69637-2 [pii]\r10.1016/S0140-6736(06)69637-2</a>.</p>
</div>
<div>
<p>Wilkinson, Thomas, Mark J. Sculpher, Karl Claxton, Paul Revill, Andrew Briggs, John A. Cairns, Yot Teerawattananon, et al. 2016. “The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought.” <em>Value in Health</em> 19 (8). Elsevier: 921–28. doi:<a href="https://doi.org/10.1016/j.jval.2016.04.015">10.1016/j.jval.2016.04.015</a>.</p>
</div>
<div>
<p>Winslow, C.-E. E, Jean Broadhurst, R. E. Buchanan, C Krumwiede, L. A. Rogers, and G. H Smith. 1920. “The Families and Genera of the Bacteria: Final Report of the Committee of the Society of American Bacteriologists on Characterization and Classification of Bacterial Types.” <em>Journal of Bacteriology</em> 5 (3): 191–229. doi:<a href="https://doi.org/10.1086/278854">10.1086/278854</a>.</p>
</div>
<div>
<p>World Health Organization Pneumonia Vaccine Trial Investigators’ Group. 2001. “Standardization of interpretation of chest radiographs for the diagnosis of pneumonia in children.” Geneva: World Health Organization. <a href="http://www.who.int/iris/handle/10665/66956" class="uri">http://www.who.int/iris/handle/10665/66956</a>.</p>
</div>
<div>
<p>Wright, AlmrothE., W. Parry Morgan, L Colebrook, and R.W. Dodgson. 1914. “Observations ON PROPHYLACTIC INOCULATION AGAINST PNEUMOCOCCUS INFECTIONS. AND ON THE RESULTS WHICH HAVE BEEN ACHIEVED BY IT.” <em>The Lancet</em> 183 (4715): 87–95. doi:<a href="https://doi.org/10.1016/S0140-6736(01)56449-1">10.1016/S0140-6736(01)56449-1</a>.</p>
</div>
<div>
<p>Wu, David Bin-Chia, Nathorn Chaiyakunapruk, Huey-Yi Chong, and Philippe Beutels. 2015. “Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: A review of economic evaluations (2006–2014).” <em>Vaccine</em> 33 (14). Elsevier Ltd: 1633–58. doi:<a href="https://doi.org/10.1016/j.vaccine.2015.01.081">10.1016/j.vaccine.2015.01.081</a>.</p>
</div>
<div>
<p>Yagupsky, P, N Porat, D Fraser, F Prajgrod, M Merires, L McGee, K P Klugman, and R Dagan. 1998. “Acquisition, Carriage, and Transmission of Pneumococci with Decreased Antibiotic Susceptibility in Young Children Attending a Day Care Facility in Southern Israel.” <em>Journal of Infectious Diseases</em> 177 (4): 1003–12. doi:<a href="https://doi.org/10.1086/515239">10.1086/515239</a>.</p>
</div>
<div>
<p>Youngster, Ilan, Jerry Avorn, Valeria Belleudi, Anna Cantarutti, Javier Díez-Domingo, Ursula Kirchmayer, Byung-Joo Park, et al. 2017. “Antibiotic Use in Children – A Cross-National Analysis of 6 Countries.” <em>The Journal of Pediatrics</em> 182 (March). Elsevier Inc.: 239–244.e1. doi:<a href="https://doi.org/10.1016/j.jpeds.2016.11.027">10.1016/j.jpeds.2016.11.027</a>.</p>
</div>
<div>
<p>Zhou, F., Abigail Shefer, J. Wenger, M. Messonnier, L. Y. Wang, A. Lopez, M. Moore, T. V. Murphy, M. Cortese, and L. Rodewald. 2014. “Economic Evaluation of the Routine Childhood Immunization Program in the United States, 2009.” <em>PEDIATRICS</em> 133 (4): 577–85. doi:<a href="https://doi.org/10.1542/peds.2013-0698">10.1542/peds.2013-0698</a>.</p>
</div>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="conclusions.html" class="navigation navigation-prev navigation-unique" aria-label="Previous page"><i class="fa fa-angle-left"></i></a>

    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/lunr.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"google": false,
"linkedin": false,
"weibo": false,
"instapper": false,
"vk": false,
"all": ["facebook", "google", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"download": ["phd_thesis.pdf", "phd_thesis.epub"],
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "";
    if (src === "" || src === "true") src = "https://cdn.bootcss.com/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:" && /^https?:/.test(src))
      src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
